DE602005022420D1 - Verfahren zur behandlung von hiv-infektion - Google Patents

Verfahren zur behandlung von hiv-infektion

Info

Publication number
DE602005022420D1
DE602005022420D1 DE602005022420T DE602005022420T DE602005022420D1 DE 602005022420 D1 DE602005022420 D1 DE 602005022420D1 DE 602005022420 T DE602005022420 T DE 602005022420T DE 602005022420 T DE602005022420 T DE 602005022420T DE 602005022420 D1 DE602005022420 D1 DE 602005022420D1
Authority
DE
Germany
Prior art keywords
hiv infection
treating hiv
treating
infection
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005022420T
Other languages
German (de)
English (en)
Inventor
Pin-Fang Lin
Beata Nowicka-Sans
Gregory Yamanaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34961940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602005022420(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of DE602005022420D1 publication Critical patent/DE602005022420D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE602005022420T 2004-03-24 2005-03-01 Verfahren zur behandlung von hiv-infektion Expired - Lifetime DE602005022420D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55576704P 2004-03-24 2004-03-24
PCT/US2005/006277 WO2005102392A2 (en) 2004-03-24 2005-03-01 Combinations for treating hiv infection

Publications (1)

Publication Number Publication Date
DE602005022420D1 true DE602005022420D1 (de) 2010-09-02

Family

ID=34961940

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005022420T Expired - Lifetime DE602005022420D1 (de) 2004-03-24 2005-03-01 Verfahren zur behandlung von hiv-infektion

Country Status (30)

Country Link
US (1) US7776863B2 (https=)
EP (1) EP1732604B1 (https=)
JP (1) JP4847441B2 (https=)
KR (1) KR101158140B1 (https=)
CN (1) CN1956720B (https=)
AR (1) AR048333A1 (https=)
AT (1) ATE474602T1 (https=)
AU (1) AU2005235116B2 (https=)
BR (1) BRPI0509140A (https=)
CA (1) CA2561146C (https=)
CY (1) CY1111613T1 (https=)
DE (1) DE602005022420D1 (https=)
DK (1) DK1732604T3 (https=)
ES (1) ES2347801T3 (https=)
GE (1) GEP20104925B (https=)
HR (1) HRP20100434T1 (https=)
IL (1) IL178141A (https=)
IN (1) IN2012DN06436A (https=)
MY (1) MY144318A (https=)
NO (1) NO337116B1 (https=)
NZ (1) NZ549778A (https=)
PE (1) PE20060148A1 (https=)
PL (1) PL1732604T3 (https=)
PT (1) PT1732604E (https=)
RU (1) RU2367439C2 (https=)
SI (1) SI1732604T1 (https=)
TW (1) TWI347184B (https=)
UA (1) UA88463C2 (https=)
WO (1) WO2005102392A2 (https=)
ZA (1) ZA200607959B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
EP2657235A1 (en) 2005-10-28 2013-10-30 Ono Pharmaceutical Co., Ltd. Compound containing basic group and use thereof
WO2007058322A1 (ja) 2005-11-18 2007-05-24 Ono Pharmaceutical Co., Ltd. 塩基性基を含有する化合物およびその用途
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US7501419B2 (en) * 2006-04-25 2009-03-10 Bristol-Myers Squibb Company 4-Squarylpiperazine derivatives as antiviral agents
US7504399B2 (en) 2006-06-08 2009-03-17 Bristol-Meyers Squibb Company Piperazine enamines as antiviral agents
US7572810B2 (en) * 2006-06-08 2009-08-11 Bristol-Myers Squibb Company Alkene piperidine derivatives as antiviral agents
JP5433691B2 (ja) * 2008-06-25 2014-03-05 ブリストル−マイヤーズ スクイブ カンパニー Ｈｉｖ結合阻害剤としてのジケトピペリジン誘導体
WO2009158394A1 (en) * 2008-06-25 2009-12-30 Bristol-Myers Squibb Company Diketo azolopiperidines and azolopiperazines as anti-hiv agents
US20110293686A1 (en) * 2010-05-28 2011-12-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-viral compositions and methods for administration
WO2012019003A1 (en) 2010-08-06 2012-02-09 Bristol-Myers Squibb Company Substituted indole and azaindole oxoacetyl piperazinamide derivatives
ES2585396T3 (es) 2010-12-02 2016-10-05 VIIV Healthcare UK (No.5) Limited Alquilamidas como inhibidores de la unión del VIH
DK2670751T3 (en) 2011-01-31 2015-07-20 Bristol Myers Squibb Co PROCEDURES FOR MANUFACTURING HIV BINDING INHIBITOR PRODUCT CONNECTION AND INTERMEDIATES
WO2012142080A1 (en) 2011-04-12 2012-10-18 Bristol-Myers Squibb Company Thioamide, amidoxime and amidrazone derivatives as hiv attachment inhibitors
US8664213B2 (en) 2011-08-29 2014-03-04 Bristol-Myers Squibb Company Spiro bicyclic diamine derivatives as HIV attachment inhibitors
WO2013033061A1 (en) 2011-08-29 2013-03-07 Bristol-Myers Squibb Company Fused bicyclic diamine derivatives as hiv attachment inhibitors
WO2013138436A1 (en) 2012-03-14 2013-09-19 Bristol-Myers Squibb Company Cyclolic hydrazine derivatives as hiv attachment inhibitors
EP2895472B1 (en) 2012-08-09 2016-11-23 VIIV Healthcare UK (No.5) Limited Tricyclic alkene derivatives as HIV attachment inhibitors
WO2014025854A1 (en) 2012-08-09 2014-02-13 Bristol-Myers Squibb Company Piperidine amide derivatives as hiv attachment inhibitors
US9586957B2 (en) * 2013-03-27 2017-03-07 VIIV Healthcare UK (No.5) Limited 2-keto amide derivatives as HIV attachment inhibitors
CN107847514A (zh) * 2015-06-23 2018-03-27 西托戴恩股份有限公司 炎症、癌症、自身免疫和其它病症中ccl5配体结合ccr5受体的抑制作用和ccr5/ccl5轴信号传导的改变
WO2023172635A1 (en) * 2022-03-08 2023-09-14 Emory University Predictive model for variants associated with drug resistance and theranostic applications thereof
US12425371B2 (en) * 2022-09-16 2025-09-23 Cisco Technology, Inc. System and method for providing SCHC-based edge firewalling

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU762404B2 (en) * 1998-03-02 2003-06-26 Panacos Pharmaceuticals, Inc. Acylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
US6476034B2 (en) 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20030207910A1 (en) 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
RU2192870C1 (ru) * 2001-07-02 2002-11-20 Закрытое акционерное общество "Агрофарм ПитерСиб" Антивирусная композиция, способ получения ее активной компоненты и способ лечения вич-инфицированных больных этой композицией
CA2469592C (en) * 2001-12-12 2005-08-23 Bristol-Myers Squibb Company Hiv integrase inhibitors
PL369856A1 (en) * 2001-12-21 2005-05-02 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy

Also Published As

Publication number Publication date
EP1732604B1 (en) 2010-07-21
HK1096540A1 (en) 2007-06-01
RU2367439C2 (ru) 2009-09-20
AU2005235116B2 (en) 2011-03-31
JP2007530540A (ja) 2007-11-01
IL178141A0 (en) 2006-12-31
IN2012DN06436A (https=) 2015-10-09
IL178141A (en) 2010-11-30
ATE474602T1 (de) 2010-08-15
US7776863B2 (en) 2010-08-17
CA2561146A1 (en) 2005-11-03
RU2006137555A (ru) 2008-04-27
TWI347184B (en) 2011-08-21
NO20064547L (no) 2006-10-06
DK1732604T3 (da) 2010-11-15
KR20070011322A (ko) 2007-01-24
CA2561146C (en) 2013-12-24
GEP20104925B (en) 2010-03-25
WO2005102392A2 (en) 2005-11-03
NZ549778A (en) 2010-09-30
MY144318A (en) 2011-08-29
ZA200607959B (en) 2008-06-25
CN1956720A (zh) 2007-05-02
HRP20100434T1 (hr) 2010-09-30
SI1732604T1 (sl) 2010-10-29
PE20060148A1 (es) 2006-03-04
PT1732604E (pt) 2010-09-24
CN1956720B (zh) 2010-12-15
AU2005235116A1 (en) 2005-11-03
AR048333A1 (es) 2006-04-19
NO337116B1 (no) 2016-01-25
EP1732604A2 (en) 2006-12-20
KR101158140B1 (ko) 2012-06-19
US20050215545A1 (en) 2005-09-29
UA88463C2 (ru) 2009-10-26
TW200538117A (en) 2005-12-01
JP4847441B2 (ja) 2011-12-28
WO2005102392A3 (en) 2006-07-20
PL1732604T3 (pl) 2010-12-31
BRPI0509140A (pt) 2007-09-04
CY1111613T1 (el) 2015-10-07
ES2347801T3 (es) 2010-11-04

Similar Documents

Publication Publication Date Title
ATE474602T1 (de) Verfahren zur behandlung von hiv-infektion
DE602004021790D1 (de) Verfahren zur behandlung von parkinson-krankheit
ATE446792T1 (de) Verfahren zur behandlung von sinuskopfschmerzen
ATE465742T1 (de) Tlr7-liganden zur behandlung von hepatitis c
DE602006018354D1 (de) Verfahren zur behandlung von abnormalem zellwachstum
ATE489955T1 (de) Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten
DE602006019753D1 (de) Verfahren und gerät zur behandlung von aneurysmen der a. thoracica
DE602007006479D1 (de) Verfahren und vorrichtungen zur behandlung von mehreren bohrlochintervallen
ATE515261T1 (de) Zusammensetzungen zur behandlung von diabetes
EP2054047A4 (en) Methods for treating acute acoustic trauma
EP1595852A4 (en) PROCESS FOR TREATING WATER CONTAINING AMMONIACAL NITROGEN
ATA17552001A (de) Verfahren zur behandlung säurehältiger abwässer
EP2046366A4 (en) METHOD OF TREATING AGE-RELATED MACULAR DEGENERATION
DE60223688D1 (de) Verfahren zur behandlung von multiplem myelom
EP1635801A4 (en) METHODS OF TREATMENT AND PREVENTION OF CARDIAC ARRHYTHMIA
EP2037736A4 (en) METHODS OF TREATING RENAL KYSTIC DISEASES
ATA6612003A (de) Verfahren zur reinigung von abwässern
EP1948675A4 (en) METHODS AND COMPOSITIONS FOR TREATING MARFAN SYNDROME AND RELATED DISORDERS
EP1786465A4 (en) METHODS FOR DETECTION AND TREATMENT OF AUTOIMMUNE DISORDERS
DE112005002653A5 (de) Verfahren zur Konfiguration von Feldgeräten
EP1848834A4 (en) PROCESS FOR PROCESSING CUPRIFER MATERIALS
DE502004008042D1 (de) Verfahren zum umformen von blechen
ATE374799T1 (de) Verfahren zur behandlung von pigmenten in partikulärer form
DE602004010548D1 (de) Verfahren zur behandlung von tierhäuten
ATE394369T1 (de) Verfahren zur aufreinigung von mesotrion